Spatial distribution of CD3- and CD8-positive lymphocytes as pretest for POLE wild-type in molecular subgroups of endometrial carcinoma.
CD3
CD8
POLE
TCGA
endometrial carcinoma
multiplex immunofluorescence
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2023
2023
Historique:
received:
28
11
2022
accepted:
07
03
2023
medline:
11
4
2023
entrez:
10
4
2023
pubmed:
11
4
2023
Statut:
epublish
Résumé
Over the years, the molecular classification of endometrial carcinoma has evolved significantly. Both POLEmut and MMRdef cases share tumor biological similarities like high tumor mutational burden and induce strong lymphatic reactions. While therefore use case scenarios for pretesting with tumor-infiltrating lymphocytes to replace molecular analysis did not show promising results, such testing may be warranted in cases where an inverse prediction, such as that of POLEwt, is being considered. For that reason we used a spatial digital pathology method to quantitatively examine CD3 We applied a four-color multiplex immunofluorescence assay for pan-cytokeratin, CD3, CD8, and DAPI on 252 endometrial carcinomas as testing and compared it to further 213 cases as validation cohort from a similar multiplexing assay. We quantitatively assessed immune infiltrates in microscopic distances within the carcinoma, in a close distance of 50 microns, and in more distant areas. Regarding prognostics, high CD3 Molecular confirmation of POLEmut cases remains the gold standard. Even if CD3
Identifiants
pubmed: 37035329
doi: 10.3389/fmed.2023.1110529
pmc: PMC10076655
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1110529Informations de copyright
Copyright © 2023 Jungen, Noti, Christe, Galvan, Zlobec, Müller, Imboden, Siegenthaler, Carlson, Pellinen, Heredia-Soto, Ruz-Caracuel, Hardisson, Redondo, Mendiola and Rau.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Gynecol Oncol. 2021 May;161(2):621-628
pubmed: 33715893
Gynecol Oncol. 2021 Sep;162(3):694-701
pubmed: 34253388
Adv Anat Pathol. 2017 Nov;24(6):311-335
pubmed: 28777143
Pathology. 2018 Apr;50(3):333-341
pubmed: 29429740
Lab Invest. 2015 Apr;95(4):377-84
pubmed: 25599534
Mod Pathol. 2020 Jul;33(7):1443-1452
pubmed: 32060377
Gynecol Oncol. 2022 May;165(2):230-238
pubmed: 35277281
Clin Cancer Res. 2019 Apr 15;25(8):2537-2548
pubmed: 30523022
Histopathology. 2016 May;68(6):916-24
pubmed: 26416160
Gynecol Oncol. 2009 Jul;114(1):105-10
pubmed: 19411095
Expert Rev Mol Diagn. 2015;15(9):1171-86
pubmed: 26289603
J Vis Exp. 2014 Sep 23;(91):51893
pubmed: 25285857
Gynecol Oncol. 2021 Aug;162(2):394-400
pubmed: 34127276
J Vis Exp. 2018 Feb 8;(132):
pubmed: 29553498
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Histopathology. 2018 Aug;73(2):327-338
pubmed: 29575153
J Pathol. 2020 Mar;250(3):312-322
pubmed: 31829447
Oncoimmunology. 2016 Dec 9;6(2):e1264565
pubmed: 28344870
Mod Pathol. 2022 Feb;35(2):256-265
pubmed: 34642425
Lab Invest. 2017 Jul;97(7):873-885
pubmed: 28504684
J Transl Med. 2012 Oct 03;10:205
pubmed: 23034130
Mod Pathol. 2021 Jan;34(1):222-232
pubmed: 32728223
J Histochem Cytochem. 2007 Jun;55(6):545-54
pubmed: 17242468
Methods. 2014 Nov;70(1):46-58
pubmed: 25242720
Front Oncol. 2022 Apr 08;12:805613
pubmed: 35463299
Sci Rep. 2017 Nov 14;7(1):15580
pubmed: 29138507
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
Anticancer Res. 2014 Oct;34(10):5555-61
pubmed: 25275055
Front Oncol. 2021 Mar 19;11:640018
pubmed: 33816285
Lab Invest. 2020 Aug;100(8):1124-1136
pubmed: 32341516
JAMA Oncol. 2015 Dec;1(9):1319-23
pubmed: 26181000
J Pathol Clin Res. 2019 Jan;5(1):63-78
pubmed: 30358171
NPJ Digit Med. 2020 May 15;3:71
pubmed: 32435699
Mod Pathol. 2019 Mar;32(3):396-404
pubmed: 30291344
J R Soc Interface. 2015 Feb 6;12(103):
pubmed: 25505134
Clin Cancer Res. 2015 Jul 15;21(14):3347-3355
pubmed: 25878334
Int J Gynecol Cancer. 2021 Jan;31(1):12-39
pubmed: 33397713
Cell. 2020 Sep 3;182(5):1341-1359.e19
pubmed: 32763154
PLoS One. 2019 Mar 27;14(3):e0214318
pubmed: 30917185
J Transl Med. 2012 Jan 03;10:1
pubmed: 22214470
J Pathol. 2020 Mar;250(3):323-335
pubmed: 31829442
Virchows Arch. 2019 Apr;474(4):511-522
pubmed: 30470933
Am J Surg Pathol. 2020 Feb;44(2):174-181
pubmed: 31651527
J Pathol Clin Res. 2017 Jan 13;3(1):58-70
pubmed: 28138402
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
Medicine (Baltimore). 2021 May 28;100(21):e26170
pubmed: 34032778
Cancer Immunol Res. 2020 Dec;8(12):1508-1519
pubmed: 32999003
Cancer Immunol Immunother. 2021 Jun;70(6):1679-1689
pubmed: 33340331
Dis Markers. 2020 Jan 28;2020:1805764
pubmed: 32076456